Research

Mixed

The SenMayo gene set (125 genes) accurately identifies senescent cells across tissues and species, and its expression levels significantly decrease following genetic or pharmacological clearance of senescent cells, serving as a reliable biomarker for senolytic efficacy.

SenMayo is a validated 125-gene signature that can detect senescent cells in various tissues (bone, brain, fat) and track their reduction after senolytic treatments (like Dasatinib + Quercetin). It is currently a research tool for monitoring senolytic efficacy, not a standard clinical test yet.

GoodSupportsHIGH confidence
SenMayo identifies senescent cells across tissues and species with high fidelity... SenMayo also represents a potentially clinically applicable panel for monitoring senescence-associated pathways across tissues and species... SenMayo demonstrates clearance of senescent cells... significant reduction in SenMayo... following D + Q treatment
Dominik Saul et al. · Nature Communications · 2022

Why this rating

Strong validation across multiple human cohorts, mouse models, and single-cell RNA-seq datasets.

Source

A new gene set identifies senescent cells and predicts senescence-associated pathways across tissues

Dominik Saul et al. · Nature Communications · 2022

DOI 10.1038/s41467-022-32552-1

mechanism_onlyCited 948×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →